

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The CheckMate 816 trial investigating neoadjuvant nivolumab with ipilimumab or chemotherapy for localized non-small cell lung cancer (NSCLC) revealed which objective response rate with nivolumab/chemotherapy?**
 - Approximately 24%
 - Approximately 34%
 - Approximately 54%
 - Approximately 64%
- 2. Which of the following drug types best describes the mechanism of action of the novel agent oclumab under investigation for unresectable Stage III NSCLC?**
 - Anti-CD79b targeted antibody
 - Anti-CD73 targeted antibody
 - Anti-PD-1 targeted antibody
 - Anti-NKG2A targeted antibody
- 3. Which overall survival (OS) result was observed with cemiplimab in the intent-to-treat population in the EMPOWER-Lung 1 study for patients with metastatic NSCLC?**
 - Median OS with cemiplimab was not reached
 - Median OS with cemiplimab was 14 months
 - Median OS with cemiplimab was 22 months
- 4. Which of the following statements is true about 4-year OS with the nivolumab/ipilimumab combination in the CheckMate 227 trial evaluating nivolumab with ipilimumab in patients with Stage IV or recurrent NSCLC?**
 - There was no OS benefit
 - Only patients with PD-L1 expression of 50% or higher had an OS benefit
 - Only patients with nonsquamous histology had an OS benefit
 - An OS benefit was found across subgroups